skip navigation

Skip Nav

Clinical Guidelines Portal

Clinical Guidelines Portal

Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents

Appendix C: Panel Roster and Financial Disclosures

HCV

(Last updated: November 1, 2012; last reviewed: November 1, 2012)

Hepatitis C Virus Infection

Member Financial Disclosure
Company Relationship
Kim, Arthur
Harvard Medical School Vertex Advisory Board
McGovern, Barbara
Tufts University Medical School (until October, 2012), Abbott Pharmaceuticals


Abbott Salary
Merck Advisory Board
Roche Speaker’s Bureau
Vertex Advisory Board
Sterling, Richard
Virginia Commonwealth University
Bayer-Onyx
Advisory Board, Research Support
Boehringer-Ingelheim
Research Support
Bristol-Myers Squibb
Research Support
Educational Concepts
Research Support
GlaxoSmithKline
Research Support
Medtronic
Research Support
Merck Advisory Board, Research Support
NOVA Speaker’s Bureau
Pfizer Research Support
Roche/Genentech
Advisory Board, Research Support
Salix Advisory Board, Consultant
Vertex Advisory Board
Sulkowski, Mark*

 
 
Johns Hopkins University

 
 
Abbott Advisory Board, Research Support
Anadys Advisory Board, Research Support
Biolex Consultant
Boehringer-Ingelheim
Advisory Board, Consultant, DSMB Member, Research Support
Bristol-Myers Squibb
Advisory Board, Research Support
Gilead Advisory Board, Research Support
GlaxoSmithKline
Advisory Board
Human Genome Sciences
Consultant
Merck Advisory Board, Research Support
Pfizer Advisory Board, Other, Research Support
Pharmasset
Research Support
Roche Advisory Board, Research Support
Teva Consultant
Tibotec Advisory Board, Research Support
Vertex Advisory Board, Research Support
Wyles, David
University of California, San Diego
Bristol-Myers Squibb
Consultant
Gilead Research Support
Janssen Pharmaceuticals
Advisory Board
Merck Consultant, Other, Research Support
Pharmasset
Research Support
Vertex Other, Research Support
*Group lead

Note: Members were asked to disclose all relationships from 24 months before the writing panel convened. The period of reporting was from June 1, 2008, through November 1, 2012.

Back to Top